Bradley Merrill Thompson, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was quoted in MobiHealthNews, in “FDA: Devs Can Release Digital Products for Psychiatric Disorders Without 510(k) Submission During COVID-19 Crisis,” by Dave Muoio.

Following is an excerpt:

What’s the Impact?

Extended periods of isolation will take a mental toll on anyone, and those who have already been diagnosed with a psychiatric condition are at an even greater risk throughout the COVID-19 emergency. Much like its prior COVID-19 guidances, yesterday’s policy update looks to increase the public’s access to lower-risk digital health tools at a time when their need is greatest.

“The FDA seems to be motivated by the fact that the primary risk of these devices ... comes from potential ineffectiveness,” Epstein Becker Green’s Bradley Merrill Thompson, who counsels on the regulation of medical devices and related products, told MobiHealthNews. “And so, during this extreme situation where demand for mental health services is dramatically outstripping supply, FDA is willing to bypass its normal regulatory requirements. That is a very practical reaction.”

Thompson (who noted that he currently represents “quite a few” developers of psychiatric disorder apps) was largely in favor of both the temporarily relaxed requirements and the longer-term wellness product clarifications. For the former, he said that the requirements that do remain in place will be time consuming enough to prevent companies from using the ongoing emergency to create and release a brand new product from scratch.

On the other hand, Thompson said that companies in a position to take advantage of the policy should worry about whether temporary launch of their treatment might introduce new difficulties when the grace period is over.

“What will FDA expect when they lift the emergency? Will they expect companies to go and rip these products out of patients’ hands? The silence in the document would suggest so,” he said. “Maybe FDA is just saying they will deal with that eventuality when it comes. But I think FDA owes companies some transparency about its intentions of what will happen. Someday this too shall pass. But companies need to know what will be expected of them when it does.”

As per the wellness guidance update, Thompson said that these clarifications generally appear to expand the number of digital health products that won’t require the regulator’s attention.

Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.